Oxford Science Enterprises is an independent investment company that finds, funds, and builds transformational science and technology companies emerging from Oxford research.
Addition led the Series B round with participation from Chevron Technology Ventures, Legal & General, Braavos Capital, and Oxford Science Enterprises.
"As we approach the culmination of the NIST project, we expect newly-ratified standards to help drive rapid adoption of PQC across the technology supply chain. Led by an industry-leading team with decades of experience, PQShield has quickly established itself as a leading authority in post-quantum cryptography for hardware and software. We are excited to see the business continue to build on its existing commercial success and further enhance its efforts in protecting our digital future."
Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.
"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."
SBI Investment led the Series B round to support the international rollout of OQC quantum platforms.
"To solve the world's most pressing challenges – from climate change to accelerated drug discovery – we need to put quantum computers in the hands of humanity and at the fingertips of our most brilliant minds. We're proud to be pioneering enterprise ready quantum with our customers, partners and investors."
The funding round was led by Oxford Science Enterprises to support growth in the US and UK markets.
"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."
— Heather Roxborough, senior partner of Health Tech
The London scaleup will use the capital to scale its presence in the United States and broaden its artificial intelligence offerings.
"AI represents one of the biggest leaps forward in technology in recent years and our unique approach to data sourcing from humans positions us to make these systems more accountable and less biased. The funding we have secured will fuel our growth in the AI space, especially in the US, bolstering our commitment to human-guided AI development during this pivotal moment in the technology’s progression."
